CN110367537A - A kind of functional food and preparation method thereof improving menopausal syndrome - Google Patents
A kind of functional food and preparation method thereof improving menopausal syndrome Download PDFInfo
- Publication number
- CN110367537A CN110367537A CN201910729202.2A CN201910729202A CN110367537A CN 110367537 A CN110367537 A CN 110367537A CN 201910729202 A CN201910729202 A CN 201910729202A CN 110367537 A CN110367537 A CN 110367537A
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- functional food
- soybean
- licorice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013376 functional food Nutrition 0.000 title claims abstract description 46
- 206010027304 Menopausal symptoms Diseases 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 239000000284 extract Substances 0.000 claims abstract description 103
- 244000068988 Glycine max Species 0.000 claims abstract description 43
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 43
- 241000202807 Glycyrrhiza Species 0.000 claims abstract description 32
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 32
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 32
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 32
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 32
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 32
- 229940010454 licorice Drugs 0.000 claims abstract description 32
- 239000002994 raw material Substances 0.000 claims abstract description 23
- 239000000463 material Substances 0.000 claims description 20
- 238000001035 drying Methods 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 14
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims description 10
- 235000008696 isoflavones Nutrition 0.000 claims description 10
- 230000001954 sterilising effect Effects 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 6
- 235000020985 whole grains Nutrition 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 3
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims description 2
- 238000007873 sieving Methods 0.000 claims description 2
- 241000219780 Pueraria Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 239000005556 hormone Substances 0.000 abstract description 8
- 229940088597 hormone Drugs 0.000 abstract description 8
- 210000002966 serum Anatomy 0.000 abstract description 7
- 210000001672 ovary Anatomy 0.000 abstract description 6
- 230000001780 adrenocortical effect Effects 0.000 abstract description 4
- 230000001294 luteotrophic effect Effects 0.000 abstract description 4
- 208000030159 metabolic disease Diseases 0.000 abstract description 4
- 231100000252 nontoxic Toxicity 0.000 abstract description 4
- 230000003000 nontoxic effect Effects 0.000 abstract description 4
- 230000002124 endocrine Effects 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 abstract description 2
- 108010057464 Prolactin Proteins 0.000 abstract description 2
- 229960005309 estradiol Drugs 0.000 abstract description 2
- 229930182833 estradiol Natural products 0.000 abstract description 2
- 229940097325 prolactin Drugs 0.000 abstract description 2
- 102000003946 Prolactin Human genes 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 230000000052 comparative effect Effects 0.000 description 13
- 235000019441 ethanol Nutrition 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 210000001235 zona fasciculata Anatomy 0.000 description 9
- 150000002515 isoflavone derivatives Chemical group 0.000 description 8
- 210000002394 ovarian follicle Anatomy 0.000 description 7
- 210000004404 adrenal cortex Anatomy 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004246 corpus luteum Anatomy 0.000 description 5
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical group C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 5
- 230000007850 degeneration Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 230000023597 hemostasis Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000003163 gonadal steroid hormone Substances 0.000 description 4
- JBQATDIMBVLPRB-UHFFFAOYSA-N isoliquiritigenin Natural products OC1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 JBQATDIMBVLPRB-UHFFFAOYSA-N 0.000 description 4
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 description 4
- YNWXJFQOCHMPCK-UHFFFAOYSA-N Isoliquiritin Natural products OC1C(O)C(O)C(CO)OC1OC(C=C1)=CC=C1C=CC(=O)C1=CC=C(O)C=C1O YNWXJFQOCHMPCK-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 3
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- HKQYGTCOTHHOMP-UHFFFAOYSA-N formononetin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O HKQYGTCOTHHOMP-UHFFFAOYSA-N 0.000 description 3
- 230000001434 glomerular Effects 0.000 description 3
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 3
- 229960004949 glycyrrhizic acid Drugs 0.000 description 3
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 3
- 235000019410 glycyrrhizin Nutrition 0.000 description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- YNWXJFQOCHMPCK-LXGDFETPSA-N isoliquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C=C1)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O YNWXJFQOCHMPCK-LXGDFETPSA-N 0.000 description 3
- 230000009245 menopause Effects 0.000 description 3
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- KSDSYIXRWHRPMN-UHFFFAOYSA-N 4'-O-beta-D-Galactopyranoside-6''-p-Coumaroylprunin-4',5,7-Trihydroxyflavanone Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC(O)=C3C(=O)C2)C=C1 KSDSYIXRWHRPMN-UHFFFAOYSA-N 0.000 description 2
- 102100021809 Chorionic somatomammotropin hormone 1 Human genes 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- 239000004378 Glycyrrhizin Substances 0.000 description 2
- 102000006771 Gonadotropins Human genes 0.000 description 2
- 108010086677 Gonadotropins Proteins 0.000 description 2
- 101000895818 Homo sapiens Chorionic somatomammotropin hormone 1 Proteins 0.000 description 2
- 101000956228 Homo sapiens Chorionic somatomammotropin hormone 2 Proteins 0.000 description 2
- 235000000421 Lepidium meyenii Nutrition 0.000 description 2
- 240000000759 Lepidium meyenii Species 0.000 description 2
- KRWXHCWICDLYOY-UHFFFAOYSA-N Licobenzofuran Natural products OC=1C=2C=C(OC)C(OC)=CC=2OC=1C1=CC=C(O)C(CC=C(C)C)=C1 KRWXHCWICDLYOY-UHFFFAOYSA-N 0.000 description 2
- MVAUGMLUJKTORM-UHFFFAOYSA-N Licoricidin Natural products COc1cc2OCC(Cc2cc1CC=C(C)C)c3ccc(O)c(CC=C(C)C)c3O MVAUGMLUJKTORM-UHFFFAOYSA-N 0.000 description 2
- FURUXTVZLHCCNA-UHFFFAOYSA-N Liquiritigenin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-UHFFFAOYSA-N 0.000 description 2
- DEMKZLAVQYISIA-ONJCETCRSA-N Liquiritin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc([C@@H]2Oc3c(C(=O)C2)ccc(O)c3)cc1 DEMKZLAVQYISIA-ONJCETCRSA-N 0.000 description 2
- DEMKZLAVQYISIA-UHFFFAOYSA-N Liquirtin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-UHFFFAOYSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 241000756042 Polygonatum Species 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 235000001671 coumarin Nutrition 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 235000007240 daidzein Nutrition 0.000 description 2
- 230000003001 depressive effect Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002213 flavones Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000002622 gonadotropin Substances 0.000 description 2
- 244000144993 groups of animals Species 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- DXDRHHKMWQZJHT-FPYGCLRLSA-N isoliquiritigenin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O DXDRHHKMWQZJHT-FPYGCLRLSA-N 0.000 description 2
- 235000008718 isoliquiritigenin Nutrition 0.000 description 2
- 235000012902 lepidium meyenii Nutrition 0.000 description 2
- GBRZTUJCDFSIHM-KRWDZBQOSA-N licoricidin Chemical compound C1([C@@H]2COC=3C=C(O)C(CC=C(C)C)=C(C=3C2)OC)=CC=C(O)C(CC=C(C)C)=C1O GBRZTUJCDFSIHM-KRWDZBQOSA-N 0.000 description 2
- GGWMNTNDTRKETA-UHFFFAOYSA-N licoricone Chemical compound COC1=C(CC=C(C)C)C(OC)=CC(O)=C1C1=COC2=CC(O)=CC=C2C1=O GGWMNTNDTRKETA-UHFFFAOYSA-N 0.000 description 2
- GYCKPTRFNFHGGO-UHFFFAOYSA-N licorinone Natural products COc1cc(O)c(C2=COc3cc(O)cc(O)c3C2=O)c(OC)c1CC=C(C)C GYCKPTRFNFHGGO-UHFFFAOYSA-N 0.000 description 2
- GBRZTUJCDFSIHM-UHFFFAOYSA-N licorisoflavan B Natural products C1C=2C(OC)=C(CC=C(C)C)C(O)=CC=2OCC1C1=CC=C(O)C(CC=C(C)C)=C1O GBRZTUJCDFSIHM-UHFFFAOYSA-N 0.000 description 2
- FURUXTVZLHCCNA-AWEZNQCLSA-N liquiritigenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-AWEZNQCLSA-N 0.000 description 2
- DEMKZLAVQYISIA-ZRWXNEIDSA-N liquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C([C@H]2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-ZRWXNEIDSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000012219 Autonomic Nervous System disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- -1 Chlorins compound Chemical class 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 1
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- PVKQULHHWVQXLE-UHFFFAOYSA-N Glycyrol Natural products C12=CC=C(O)C=C2OC2=C1C(=O)OC1=C2C(O)=C(CC=C(C)C)C(OC)=C1 PVKQULHHWVQXLE-UHFFFAOYSA-N 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- XQWFHGOIUZFQPJ-USTPAGJBSA-N Neoisoliquiritigenin Natural products O=C(/C=C/c1ccc(O)cc1)c1c(O)cc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O2)cc1 XQWFHGOIUZFQPJ-USTPAGJBSA-N 0.000 description 1
- XQWFHGOIUZFQPJ-LXGDFETPSA-N Neoisoliquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C=C1O)=CC=C1C(=O)\C=C\C1=CC=C(O)C=C1 XQWFHGOIUZFQPJ-LXGDFETPSA-N 0.000 description 1
- XQWFHGOIUZFQPJ-UHFFFAOYSA-N Neoisoliquiritin Natural products OC1C(O)C(O)C(CO)OC1OC(C=C1O)=CC=C1C(=O)C=CC1=CC=C(O)C=C1 XQWFHGOIUZFQPJ-UHFFFAOYSA-N 0.000 description 1
- HJBUYKZTEBZNSH-ZRWXNEIDSA-N Neoliquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C(=O)C[C@H](O2)C=3C=CC(O)=CC=3)C2=C1 HJBUYKZTEBZNSH-ZRWXNEIDSA-N 0.000 description 1
- HJBUYKZTEBZNSH-ONJCETCRSA-N Neoliquiritin Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C(=O)C[C@@H](O2)C=3C=CC(O)=CC=3)C2=C1 HJBUYKZTEBZNSH-ONJCETCRSA-N 0.000 description 1
- 206010030247 Oestrogen deficiency Diseases 0.000 description 1
- 206010058667 Oral toxicity Diseases 0.000 description 1
- 235000008737 Polygonatum biflorum Nutrition 0.000 description 1
- 102100024819 Prolactin Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000007613 Shoulder Pain Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- RIKPNWPEMPODJD-UHFFFAOYSA-N formononetin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC=C2C1=O RIKPNWPEMPODJD-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- LWESBHWAOZORCQ-UHFFFAOYSA-N glycyrol Chemical compound C12=CC=C(O)C=C2OC2=C1C(=O)OC1=C2C(OC)=C(CC=C(C)C)C(O)=C1 LWESBHWAOZORCQ-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100000150 mutagenicity / genotoxicity testing Toxicity 0.000 description 1
- 230000003557 neuropsychological effect Effects 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000005186 women's health Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Botany (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention provides a kind of functional food and preparation method thereof for improving menopausal syndrome, and the functional food is by including that the raw material of following components is made: kudzu root extract, extract of soybean, licorice and Rhizoma Polygonati extract.Functional food of the invention is by combining kudzu root extract, extract of soybean, licorice and Rhizoma Polygonati extract, include a variety of endocrine metabolic diseases reparative factors naturally extracted, synergistic effect is played each other, effectively improve estradiol level in serum, reduce luteotropic hormone, Folliculogenesis hormone and prolactin levels, improve the adrenocortical form of ovary and function, to achieve the effect that improve menopausal syndrome, and totally nontoxic side effect.
Description
Technical field
The present invention relates to field of functional food, eat more particularly, to a kind of the functional of conditioning menopausal syndrome
Product and preparation method thereof.
Background technique
Menopausal syndrome (MPS) is also known as perimenopausal syndrome, refers to and sex hormone fluctuation occurs before and after postmenopausal women or subtract
It is a series of based on function disorder of autonomic nervous system caused by few, with one group of syndrome of neuropsychological symptom.
Climacteric is almost the physiological periods that each women will be undergone, but the attitude of many people is " to have crossed this burst of youngster
It is all right ", ignore influence of the climacteric to women's health.Specifically, climacteric can be divided into the health effect of women
Three phases: recent, mid-term and long term.
Outcome: the namely menopause symptom usually said of people.These symptoms include night sweat, fever, palpitaition etc.,
Even temperish, insomnia, some women can also feel oneself, and uncomfortable shoulder pain or throat do not relax from head to foot
Clothes or joint are felt bad.And go to hospital to check each organ all there is no problem.This is all because estrogen deficiency causes in fact
Uncomfortable and emotional change.
Mid-term influences: starting from body surface, wrinkle increases, and waistline increases, and figure is got fat.The shortage of estrogen can make
Female body generates a series of variations, as collagen is largely lost, wrinkle generates, figure is got fat, urogenital system atrophy
Etc., this is also the problem of women most worries.
Remote effect: climacteric endangers maximum influence or osteoporosis to women.This is because estrogen not only has
Reproductive function also has metabolic function, and osteoporosis is actually a kind of metabolic disorder of calcium.In addition, the postmenopausal women heart
Vascular diseases risk can also increase.
Climacteric medical association, the world selectes annual October 18 as " world's climacteric shows loving care for day ", appeals that various circles of society are total
With concern Menopause health, Menopause health care is carried out.The drug of relieving menopausal syndrome in the prior art
Or health care product is more, but mostly curative effect is general.
Summary of the invention
In view of the problems of the existing technology, the present invention provide it is a kind of improve menopausal syndrome functional food and its
Preparation method.
The present invention provides a kind of functional food for improving menopausal syndrome, is made by the raw material for including following components:
Kudzu root extract, extract of soybean, licorice and Rhizoma Polygonati extract.
Kudzu root extract of the present invention is the alcohol extract of pueraria lobata, and extracting method is this field general extraction methods.Specifically
It can are as follows: pueraria lobata is taken, coarse powder is ground into, adds 30% ethyl alcohol heating and refluxing extraction twice, 2 hours every time, for the first time plus 10 times were measured, the
Secondary plus 8 times of amounts, filtration, merging filtrate, it is the clear of 1.10~1.20 (room temperatures) that filtrate, which is concentrated under reduced pressure into relative density in 60 DEG C,
Cream is let cool, and ethyl alcohol is added to make alcohol content 70%, is stood 12 hours, is taken supernatant, ethyl alcohol is recovered under reduced pressure, and be concentrated into thick paste, is done
It is dry, crush to get.The kudzu root extract contains a variety of flavones ingredients, and main active is daidzein (daidzein), greatly
Beans glucoside (daidzin), Puerarin (puerarin), Puerarin -7- xyloside (puerarin-7-xyloside).
Extract of soybean of the present invention is the water-alcohol extract of soybean, and extracting method can are as follows: soybean germ or dregs of beans are through powder
Broken, tinning, 80% alcohol-water is solvent, and heating and refluxing extraction three times, 2 hours every time, merges extracting solution three times, recycles ethyl alcohol
To no alcohol, continue the medicinal extract for evaporating water to specific gravity d=1.20, medicinal extract cools, and three times with water-saturated n-butanol extraction, merges positive fourth
Alcohol item recycles n-butanol to no alcohol, and medicinal extract dry, pulverize, and be sieved up to extract of soybean powder.The extract of soybean master
Wanting active constituent is isoflavones.
Licorice of the present invention is the water extract of Radix Glycyrrhizae, and extracting method can are as follows: crude drug is handled as net medicinal material,
It adds water to cook 3 times, 1.5 hours every time, filtration, merging filtrate, filtrate was concentrated under reduced pressure into relative density with 60 DEG C or less and is
The clear cream of 1.10-1.20 (room temperature), lets cool, and 4 times of amount ethyl alcohol are added, stir evenly, and stands 2 hours, and filtration, filtrate decompression recycles second
Alcohol, filter extracting solution, be added concentration tank in be concentrated, spray drying to get.The licorice master contains triterpenoid saponin, mainly
Including glycyrrhizin (glycyrrhizin), uralsaponin (uralsaponin) and glycyrrhizic acid
(licoricesaponin)；Chlorins compound containing flavones again: liquiritigenin (liquiritigenin), liquiritin
(liquiritin), Isoliquiritigenin (isoliquiritigenin), isoliquiritin (isoliquiritin), neoliquriitin
(neoliquiritin), close isoliquiritin (neoisoliquiritin), licoricidin (licoricidin), Licoricone
(licoricone), formoononetin (formononetin etc.；Also compound containing Coumarins: Radix Glycyrrhizae coumarin
(glycycoum-arim), glycyol (glycyrol) etc.；Again containing alkaloid, licobenzofuran (licobenzofuran),
Radix Glycyrrhizae glucan GBW (glucan GBW), licorice polysaccharide (glycyrrigan) etc..
Rhizoma Polygonati extract of the present invention is the water extract of rhizoma polygonati, the same licorice of extracting method.The rhizoma polygonati extracts
Object contains steroid saponin, Siberian solomonseal rhizome polysaccharide A, B, C, and A containing polygonatum rhizome oligosaccharide, B, C etc..
Functional food of the invention is by by kudzu root extract, extract of soybean, licorice and Rhizoma Polygonati extract
Combination, includes a variety of endocrine metabolic diseases reparative factors naturally extracted, plays synergistic effect each other, effectively improves female in serum
Glycol (E2) horizontal, luteotropic hormone (LH), Folliculogenesis hormone (FSH) and lactogen (PRL) level are reduced, ovum is improved
The adrenocortical form of nest and function, to achieve the effect that improve menopausal syndrome, and totally nontoxic side effect, also not
Lead to the risk of minor depressive in the presence of long-term use.
Preferably, the functional food is made: kudzu root extract in parts by weight by the raw material for including following components
20~50 parts, 20~40 parts of extract of soybean, 10~30 parts of licorice and 10~30 parts of Rhizoma Polygonati extract.Each component is limited
Determine within the above range, it is more preferable that products obtained therefrom improves menopausal syndrome effect.
Preferably, the content of the Isoflavone in Extract of Soybean is 25%~80%.
In a preferred embodiment of the invention, the functional food, in parts by weight, by the original including following components
Material is made: 40~50 parts of kudzu root extract, 20~30 parts of extract of soybean, 20~30 parts of licorice and Rhizoma Polygonati extract 10
~15 parts.
In a preferred embodiment of the invention, the functional food, in parts by weight, by including following components
Raw material is made: 50 parts of kudzu root extract, 30 parts of extract of soybean, 20 parts of licorice and 10 parts of Rhizoma Polygonati extract.
In presently preferred embodiment, the functional food, in parts by weight, by including following components
Raw material be made: 40 parts of kudzu root extract, 25 parts of extract of soybean, 25 parts of licorice and 10 parts of Rhizoma Polygonati extract.
Preferably, the dosage form of the functional food is capsule, tablet or electuary.
The present invention also provides a kind of preparation methods of above-mentioned functional food, comprising: according to the ratio by powdered each component
It is mixed, target formulation is made in drying and sterilizing, whole grain and 60~100 meshes excessively, the gained fine powder that will finally be sieved.
Above-mentioned preparation method simple process, and the influence of the active constituent of each raw material component will be preferably minimized, make obtained
Product efficacy is best.
Preferably, water content is 15~30wt% before each component is mixed.
Preferably, material moisture is less than 5wt% after the drying and sterilizing.
Preferably, the drying and sterilizing carries out 30~45min at being 60~80 DEG C in temperature.
Preferably, the sieving was 80 meshes.
Functional food of the invention is by by kudzu root extract, extract of soybean, licorice and Rhizoma Polygonati extract
Combination, includes a variety of endocrine metabolic diseases reparative factors naturally extracted, plays synergistic effect each other, effectively improves female in serum
Glycol level reduces luteotropic hormone, Folliculogenesis hormone and prolactin levels, improves the adrenocortical form of ovary
And function, to achieve the effect that improve climacteric syndrome, in addition, product of the present invention can also prevent risk of cardiovascular diseases；
And totally nontoxic side effect, also there is no take the risk for leading to minor depressive for a long time.
Specific embodiment
Combined with specific embodiments below, specific embodiments of the present invention will be described in further detail.Following embodiment
For illustrating the present invention, but it is not intended to limit the scope of the invention.
In the present invention, parts by weight can be the unit of weight well known in the art such as μ g, mg, g, kg, be also possible to it again
Number, such as 1/10,1/100,10 times, 100 times.
Kudzu root extract, extract of soybean, licorice and Rhizoma Polygonati extract in the embodiment of the present invention are powder
Shape raw material, by commercially available.
Embodiment 1
The present embodiment provides a kind of functional foods for improving menopausal syndrome, in parts by weight, by following raw material system
: 50 parts of kudzu root extract, 30 parts of extract of soybean, 20 parts of licorice and 10 parts of Rhizoma Polygonati extract, wherein soybean is extracted
The content of isoflavones is 40% in object.
The present embodiment also provides the preparation method of above-mentioned functional food, comprising the following steps:
(1) qualified kudzu root extract, extract of soybean, licorice and Rhizoma Polygonati extract will be examined to press said ratio
It puts into blender, 20min is stirred with 24r/min, and controlling raw material moisture content is 10wt%；
(2) material mixed is uniformly laid in vacuum desiccator by the thickness of 2cm again, in temperature 60 C, time
It is sterilized and is dried under the conditions of 45min, moisture content of material is less than 5wt% after drying；
(3) material after drying and sterilizing is subjected to whole grain, crosses 80 meshes and obtains fine powder；
(4) it requires fine powder capsule or tablet or electuary is made according to functions of the state food technology, be packed.
Embodiment 2
The present embodiment provides a kind of functional foods for improving menopausal syndrome, in parts by weight, by following raw material system
: 40 parts of kudzu root extract, 25 parts of extract of soybean, 25 parts of licorice and 10 parts of Rhizoma Polygonati extract, wherein soybean is extracted
The content of isoflavones is 50% in object.
The present embodiment also provides the preparation method of above-mentioned functional food, comprising the following steps:
(1) qualified kudzu root extract, extract of soybean, licorice and Rhizoma Polygonati extract will be examined to press said ratio
It puts into blender, 20min is stirred with 24r/min, and controlling raw material moisture content is 20wt%；
(2) material mixed is uniformly laid in vacuum desiccator by the thickness of 2cm again, in 80 DEG C of temperature, time
It is sterilized and is dried under the conditions of 30min, moisture content of material is less than 5wt% after drying；
(3) material after drying and sterilizing is subjected to whole grain, crosses 80 meshes and obtains fine powder；
(4) it requires fine powder capsule or tablet or electuary is made according to functions of the state food technology, be packed.
Embodiment 3
The present embodiment provides a kind of functional foods for improving menopausal syndrome, in parts by weight, by following raw material system
: 30 parts of kudzu root extract, 30 parts of extract of soybean, 25 parts of licorice and 15 parts of Rhizoma Polygonati extract, wherein soybean is extracted
The content of isoflavones is 40% in object.
The present embodiment also provides the preparation method of above-mentioned functional food, comprising the following steps:
(1) qualified kudzu root extract, extract of soybean, licorice and Rhizoma Polygonati extract will be examined to press said ratio
It puts into blender, 20min is stirred with 24r/min, and controlling raw material moisture content is 20wt%；
(2) material mixed is uniformly laid in vacuum desiccator by the thickness of 2.2cm again, temperature 70 C, when
Between sterilized and dried under the conditions of 40min, moisture content of material is less than 5wt% after drying；
(3) material after drying and sterilizing is subjected to whole grain, crosses 80 meshes and obtains fine powder；
(4) it requires fine powder capsule or tablet or electuary is made according to functions of the state food technology, be packed.
Embodiment 4
The present embodiment provides a kind of functional foods for improving menopausal syndrome, in parts by weight, by following raw material system
: 40 parts of kudzu root extract, 30 parts of extract of soybean, 20 parts of licorice and 10 parts of Rhizoma Polygonati extract, wherein soybean is extracted
The content of isoflavones is 60% in object.
The present embodiment also provides the preparation method of above-mentioned functional food, comprising the following steps:
(1) qualified kudzu root extract, extract of soybean, licorice and Rhizoma Polygonati extract will be examined to press said ratio
It puts into blender, 20min is stirred with 24r/min, and controlling raw material moisture content is 20wt%；
(2) material mixed is uniformly laid in vacuum desiccator by the thickness of 2cm again, in 65 DEG C of temperature, time
It is sterilized and is dried under the conditions of 50min, moisture content of material is less than 7wt% after drying；
(3) material after drying and sterilizing is subjected to whole grain, crosses 80 meshes and obtains fine powder；
(4) it requires fine powder capsule or tablet or electuary is made according to functions of the state food technology, be packed.
Embodiment 5
The present embodiment provides a kind of functional foods for improving menopausal syndrome, in parts by weight, by following raw material system
: 20 parts of kudzu root extract, 20 parts of extract of soybean, 40 parts of licorice and 20 parts of Rhizoma Polygonati extract, wherein soybean is extracted
The content of isoflavones is 60% in object.Preparation method is the same as embodiment 1.
Embodiment 6
The present embodiment provides a kind of functional foods for improving menopausal syndrome, in parts by weight, by following raw material system
: 10 parts of kudzu root extract, 10 parts of extract of soybean, 30 parts of licorice and 50 parts of Rhizoma Polygonati extract, wherein soybean is extracted
The content of isoflavones is 70% in object.Preparation method is the same as embodiment 1.
Embodiment 7
The present embodiment provides a kind of functional foods for improving menopausal syndrome, in parts by weight, by following raw material system
: 15 parts of kudzu root extract, 15 parts of extract of soybean, 10 parts of licorice and 60 parts of Rhizoma Polygonati extract, wherein soybean is extracted
The content of isoflavones is 70% in object.Preparation method is the same as embodiment 1.
Comparative example 1
This comparative example provides a kind of functional food, in parts by weight, is made by following raw material: 50 parts of kudzu root extract,
30 parts of extract of soybean, 20 parts of licorice and 10 parts of Maca extract.Preparation method is the same as embodiment 1.
Comparative example 2
This comparative example provides a kind of functional food, in parts by weight, is made by following raw material: 40 parts of kudzu root extract,
30 parts of extract of soybean, 20 parts of Maca extract and 10 parts of Rhizoma Polygonati extract.Preparation method is the same as embodiment 1.
Comparative example 3
This comparative example provides a kind of functional food, in parts by weight, is made by following raw material: 50 parts of kudzu root extract,
30 parts of extract of soybean, 20 parts of licorice and 5 parts of Turmeric P.E.Preparation method is the same as embodiment 1.
Test example
Toxotest
Oral toxicity test, binomial mutagenicity test (mouse have been carried out to the functional food of the embodiment of the present invention 1~7
Polychromatic erythrocyte number micronucleus test and sperm malformation test) and 30 days feeding trials safety evaluatio experiment and disease
Tissue examination and gross anatomy test are managed, test data does not find that given the test agent has apparent toxic effect, by acute toxicity
Grade scale evaluation, the given the test agent belong to nontoxic grade.
Functional experiment test
Efficacy test is carried out to the functional food of the embodiment of the present invention 1~7 and comparative example 1~3 respectively, specific as follows:
1 material
1.1 drugs and reagent
Test sample: the functional food of the embodiment of the present invention 1~7 is provided by Kazakhstan Foucault skill (Wuhan) Group Co., Ltd,
Human body recommended amounts 50mg/kg*d；The functional food of comparative example 1~3.
Western medicine: diaethyl stilbestroli tablet is produced by Guangzhou Qiaoguang Pharmaceutical Plant, lot number: 180803.
Reagent: sex hormone, which is put, exempts from batch pan and is provided by northern immunoreagent research institute.
1.2 experimental animals and grouping
It selects 140 months 11~l5 of monthly age, weight 280~350g female sd inbred rats, Via vagina cell smear inspection, presents
The irregular oestrous cycle is determined as climacteric mouse.Be assigned randomly to climacteric group, 1 functional food of embodiment it is high, medium and low
Dosage group and 2,3,4,5,6,7 groups of embodiment and Western medicine group and 1,2,3 group of comparative example, every group 10.The optionally monthly age 3~5
The moon, 150~210g of weight female sd inbred rats 10 are only used as young control, and all female sd inbred rats are by Hubei Province experimental animal
The heart provides, cleaning grade.
2 experimental methods
2.1 medication
(1) physiological saline 2ml/l00g weight stomach-filling, one time a day, continuous 8 weeks climacteric group: are given；
(2) low, middle and high dose groups of 1 functional food of embodiment: the functional food 0.5g/kg of embodiment 1 is given
Bw, 1.0g/kgbw, 2.0g/kgbw, continuous 8 weeks；
2,3,4,5,6,7 groups of embodiment: give respective sample 2.0g/kgbw respectively, continuous 8 weeks；
(3) Western medicine group: being dissolved in water with diethylstilbestrol tablet, and 12.5 μ g/ml are made, and gives 2ml/l00g weight stomach-filling, often
Day 1 time, continuous 8 weeks；
(4) 1,2,3 group of comparative example: giving respective sample 2.0g/kgbw respectively, and continuous 8 weeks；
(5) young control: any processing is not given.
2.2 index observings and measurement
Sacrificed by decapitation groups of animals takes blood, extracts ovary, adrenal gland is detected and observed.
Serum Sex Hormones, Gonadotropin Level measurement:
Sacrificed by decapitation groups of animals, blood sampling prepare serum, and every part of sample measures E respectively2, LH, FSH, PRL, all with radiation
Immunization, the sample of animal subject operate by specification with a batch measurement.
The om observation of ovary tissue slice:
The each group rats with bilateral ovary extractd is fixed with formalin, paraffin embedding, slice, piece is 6 μm thick, HE dye
Color, high power microscopic observation primordial follicle, primary follicle, secondary follicle and the corpus luteum of normal development and degeneration, and observe ovum at different levels
Cyto-architectural variation in bubble.
The om observation of interrenal tissue's slice:
The each group adult rat adrenal tissue extractd is fixed with 4% formalin, paraffin embedding, slice, piece is 6 μm thick, HE
It dyes, om observation tissue change, gland cortical thickness on arm is measured under high power lens and counts cellular lipids drop number.
Glomerular zone, reticular zone, zona fasciculata thickness coefficient: the adrenal cortex through thickness measured under high power lens, divided by spherical
Ratio obtained by band, reticular zone and each tape thickness of zona fasciculata is set to the thickness coefficient of the band.
The judgment criteria of zona fasciculata class fat drips content: "+", 200, the stockaded village high power lens Xia Guan zona fasciculata cell simultaneously count its born of the same parents
The cell that matter includes 4 or less class fat drips accounts for 70 or more persons in 200 cells；" ++ ", the cell containing 5~9 class fat drips account for
70 or more persons in 200 cells；" +++ ", the cell containing 10 or more class fat drips account for 70 or more persons in 200 cells.
The judgment criteria of hemostasis degree: "+" is full of haemocyte in blood sinus, but blood sinus is unexpanded；" ++ " is full of in blood sinus
Haemocyte, while being expanded with blood sinus.
2.3 data processing
As a result it is indicated with x ± s, conspicuousness is compared using SPSS11.5 statistical package, examined using t.
3 experimental results
The variation of 3.1 each group Serum Sex Hormones, Gonadotropin Level, is shown in Table 1
1 each group rat blood serum E of table2, LH, FSH, PRL measurement result
Note: compared with young control, △ △ P < 0.01；Compared with climacteric group, * P < 0.05, * * P < 0.01.
As shown in Table 1, compared to young control, climacteric group E2It is substantially reduced (P < 0.01), LH apparent increase (P <
0.01), FSH increase but it is not statistically significant, PRL obviously rises (P < 0.01).Compared to climacteric group, embodiment 1 is functional
The low, middle and high dose groups and Western medicine group E of food2Level improves (P < 0.01), indifference between group；LH level reduce (P < 0.05 and
0.01), high dose group FSH reduces (P < 0.05), remaining group can also reduce, but not statistically significant；The reduction of PRL level (P <
0.05 and 0.01).2,3,4,5,6,7 groups of E of embodiment2Level improves, 2,3,4 groups of significant effects (P < 0.01) of embodiment, implements
5,6,7 groups of example (P < 0.05)；LH level reduces, 2,3,4 groups of significant effects (P < 0.01) of embodiment, 5,6,7 groups of embodiment (P <
0.05)；FSH is reduced, and 2,3,4 groups of effects of embodiment are obvious (P < 0.05), and 5,6,7 groups of effects of embodiment are unobvious, do not have statistics
Learn meaning；PRL level reduces, 2,3,4 groups of significant effects (P < 0.01) of embodiment, 5,6,7 groups of embodiment (P < 0.05)；Comparative example
1, E can also be improved for 2,3 groups2It is horizontal to reduce LH, FSH and PRL for level, but effect is not significant.
The change of 3.2 ovarian morphologys
Climacteric group primordial follicle is few, and degeneration ovarian follicle is more, and normotrophic ovarian follicle is few, and corpus luteum quantity is few；Embodiment 1 is low,
Middle and high dosage group and 2,3,4 groups of normotrophic ovarian follicles of embodiment are more, and growing follicle increases, and degeneration ovarian follicle is few, corpus luteum quantity
It is more；5,6,7 groups of primary growth ovarian follicles of embodiment are still more, and secondary and graaffian follicle is less, and corpus luteum is less；Western medicine group growing follicle
Shang Duo, degeneration ovarian follicle are more；Young control primordial follicle is more, and primary follicle is more；1,2,3 group of primary growth ovarian follicle of comparative example is still
More, secondary and graaffian follicle is few, and corpus luteum is few.
The change of 3.3 each group Rat Adrenal Cortex forms and function, is shown in Table 2 and table 3
2 each band of each group Rat Adrenal Cortex of table accounts for the measurement result of cortex full thickness
Note: compared with young control, △ △ P < 0.01；Compared with climacteric group, * P < 0.05, * * P < 0.01.
The observation result of 3 each group Rat Adrenal Cortex class fat drips content of table and hemostasis
By table 2,3 it is found that climacteric group adrenal cortex glomerular zone, reticular zone are thickened compared with young control, zona fasciculata becomes
Thin, zona fasciculata cell rope loses the design feature being arranged parallel to each other and intersects in net, the interior especially nearly pencil zone of reticular zone
Hemostasis is obvious, and class fat drips content significantly reduces in zona fasciculata cell cytoplasm.1 low, middle and high dose groups of embodiment and embodiment 2,3,
4,5,6,7 groups compared with climacteric group, glomerular zone, reticular zone are thinning, and zona fasciculata thickens (P < 0.01), zona fasciculata cell rope form
Normal, for class fat drips content close to young control, reticular zone has no obvious hemostasis.Western medicine group has adrenal cortex thickness
Improve, class fat drips content can also increased, but can cause reticular zone cystis degeneration and hemostasis.1,2,3 group of comparative example to adrenal gland
Cortical thickness has improvement, class fat drips content can also increased, but effect is not significant.
Show that product of the invention can improve estradiol (E by above-mentioned experiment2) horizontal, reduce luteotropic hormone
(LH), Folliculogenesis hormone (FSH) and lactogen (PRL) are horizontal, improve the adrenocortical form of ovary and function, thus
Achieve the effect that improve menopausal syndrome.
The following are typical cases:
Mrs Liu, 49 years old, hospital's medical check was gone in menstruation irregularis half a year, general weakness, agitation, hectic fever hidrosis, diagnosis
For menopausal syndrome.After taking 1 product of the embodiment of the present invention 3 months (3.0g/d), the symptom of Liu Nvshi is substantially reduced.It is several
When checking again after month, Liu Nvshi has had rosy cheeks, is full of energy, and malaise symptoms all disappear before.
Mrs Qiu, 47 years old, dreaminess of often sleeping was vexed out of strength, daily continuous perspiration, and clothing is wet to the greatest extent, and sweating is with Head And Face
Based on, lassitude, food of receiving is reduced, four limbs lassitude.With hospital admission is removed, be diagnosed as menopausal syndrome, once in, west
It cures and treats a Nian Youyu, produce effects unobvious.It takes 1 product of the embodiment of the present invention 3 months (3.0g/d) and sleeps afterwards good and sound, sweating is big
Subtract, spirit improves.Edible by 6 months, all are good and sound, without hidrosis, physical rehabilitation.
Mrs Huang, it is 51 years old, thin beautiful, it has a graceful deportment, but skin of face is dim mute unglazed, interest is unable to lift to things, instead
Should be slightly slow, often feel uncomfortable in chest, shortness of breath, be easy fatigue, diarrhea, not good enough, the symptoms such as climacteric hectic fever, perspiration of sleeping.After diagnosing, Huang Nv
Scholar results in menopausal syndrome since internal hormone is unbalance.After taking 1 product of the embodiment of the present invention 3 months (3.0g/d),
The symptom of Mrs Huang is substantially reduced.When checking again after taking 6 months, Mrs Huang is uncomfortable in chest, shortness of breath, is easy fatigue, diarrhea, and sleep is owed
Good, malaise symptoms all disappear before climacteric hectic fever, perspiration etc., and skin smooth is energetic.
Finally, method of the invention is only preferable embodiment, it is not intended to limit the scope of the present invention.It is all
Within the spirit and principles in the present invention, any modification, equivalent replacement, improvement and so on should be included in protection of the invention
Within the scope of.
Claims (10)
1. a kind of functional food for improving menopausal syndrome, which is characterized in that be made by the raw material for including following components: Pueraria lobota
Root extract, extract of soybean, licorice and Rhizoma Polygonati extract.
2. functional food according to claim 1, which is characterized in that in parts by weight, by the original including following components
Material is made: 20~50 parts of kudzu root extract, 20~40 parts of extract of soybean, 10~30 parts of licorice and Rhizoma Polygonati extract 10
~30 parts.
3. functional food according to claim 1 or 2, which is characterized in that the Isoflavone in Extract of Soybean
Content be 25%~80%.
4. functional food according to claim 3, which is characterized in that in parts by weight, by the original including following components
Material is made: 40~50 parts of kudzu root extract, 20~30 parts of extract of soybean, 20~30 parts of licorice and Rhizoma Polygonati extract 10
~15 parts.
5. functional food according to claim 4, which is characterized in that in parts by weight, by the original including following components
Material is made: 50 parts of kudzu root extract, 30 parts of extract of soybean, 20 parts of licorice and 10 parts of Rhizoma Polygonati extract；
Or, the functional food is made: 40 parts of kudzu root extract, soybean in parts by weight by the raw material for including following components
25 parts of extract, 25 parts of licorice and 10 parts of Rhizoma Polygonati extract.
6. described in any item functional foods according to claim 1~5, which is characterized in that the dosage form of the functional food
For capsule, tablet or electuary.
7. the preparation method of the described in any item functional foods of claim 1~6 characterized by comprising will be powdered
Each component is mixed according to the ratio, target is made in drying and sterilizing, whole grain and 60~100 meshes excessively, the gained fine powder that will finally be sieved
Dosage form.
8. preparation method according to claim 7, which is characterized in that before each component is mixed water content be 15~
30wt%；
And/or material moisture is less than 5wt% after the drying and sterilizing.
9. preparation method according to claim 7, which is characterized in that the drying and sterilizing temperature be 60~80 DEG C at into
30~60min of row.
10. preparation method according to claim 7, which is characterized in that the sieving was 80 meshes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910729202.2A CN110367537A (en) | 2019-08-08 | 2019-08-08 | A kind of functional food and preparation method thereof improving menopausal syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910729202.2A CN110367537A (en) | 2019-08-08 | 2019-08-08 | A kind of functional food and preparation method thereof improving menopausal syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110367537A true CN110367537A (en) | 2019-10-25 |
Family
ID=68258680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910729202.2A Pending CN110367537A (en) | 2019-08-08 | 2019-08-08 | A kind of functional food and preparation method thereof improving menopausal syndrome |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110367537A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115590140A (en) * | 2021-06-28 | 2023-01-13 | 江苏京森生物医药新材料科技有限公司（Cn） | Health-care functional food for regulating female endocrine balance and relieving climacteric syndrome and irregular menstruation |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030157199A1 (en) * | 2001-07-31 | 2003-08-21 | Daicho Kikaku Incorporated Company | Health food products |
| US20060222721A1 (en) * | 2005-04-01 | 2006-10-05 | Bionovo, Inc. | Composition for treatment of menopause |
| CN101972400A (en) * | 2010-10-08 | 2011-02-16 | 河南中医学院 | Application of sealwort extract to preparing medicament for treating women climacteric metancholia caused by in vivo female hormore hyposecretion |
| CN103070940A (en) * | 2012-12-26 | 2013-05-01 | 东莞市照燕生物科技有限公司 | Nutritional health-care product for improving menopausal symptoms |
| CN104001052A (en) * | 2014-06-09 | 2014-08-27 | 杨献华 | Traditional Chinese medicine composition for treating climacteric syndrome |
| CN104223304A (en) * | 2014-09-30 | 2014-12-24 | 无锡康顿生物科技有限公司 | Product capable of relieving nerves and improving menopausal symptoms and preparation method thereof |
| KR101906720B1 (en) * | 2017-04-14 | 2018-10-10 | 김대현 | Composition comprising the combination extract of Lycium chinensis, Glycyrrhiza urlaensis FISCH, Foeniculum vulagare MILL, Glycine max MERR, and Pueraria thunbergiana BENTH for preventing and treating menopause-related disease and depression |
-
2019
- 2019-08-08 CN CN201910729202.2A patent/CN110367537A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030157199A1 (en) * | 2001-07-31 | 2003-08-21 | Daicho Kikaku Incorporated Company | Health food products |
| US20060222721A1 (en) * | 2005-04-01 | 2006-10-05 | Bionovo, Inc. | Composition for treatment of menopause |
| CN101972400A (en) * | 2010-10-08 | 2011-02-16 | 河南中医学院 | Application of sealwort extract to preparing medicament for treating women climacteric metancholia caused by in vivo female hormore hyposecretion |
| CN103070940A (en) * | 2012-12-26 | 2013-05-01 | 东莞市照燕生物科技有限公司 | Nutritional health-care product for improving menopausal symptoms |
| CN104001052A (en) * | 2014-06-09 | 2014-08-27 | 杨献华 | Traditional Chinese medicine composition for treating climacteric syndrome |
| CN104223304A (en) * | 2014-09-30 | 2014-12-24 | 无锡康顿生物科技有限公司 | Product capable of relieving nerves and improving menopausal symptoms and preparation method thereof |
| KR101906720B1 (en) * | 2017-04-14 | 2018-10-10 | 김대현 | Composition comprising the combination extract of Lycium chinensis, Glycyrrhiza urlaensis FISCH, Foeniculum vulagare MILL, Glycine max MERR, and Pueraria thunbergiana BENTH for preventing and treating menopause-related disease and depression |
Non-Patent Citations (5)
| Title |
|---|
| 吴楠等: "围绝经期激素替代治疗的现状研究", 《人民军医》 * |
| 周丽等: "黑升麻治疗围绝经期综合征的研究进展", 《中西医结合研究》 * |
| 周媛媛等: "黄精多糖对12月龄自然更年期大鼠血脂及血清SOD、MDA影响的实验研究", 《卫生职业教育》 * |
| 李林等: "植物雌激素的筛选及抗皮肤老化的体外研究", 《上海交通大学学报(医学版)》 * |
| 袁婷婷等: "天然药物中植物雌激素样化学成分的研究进展", 《中国中药杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115590140A (en) * | 2021-06-28 | 2023-01-13 | 江苏京森生物医药新材料科技有限公司（Cn） | Health-care functional food for regulating female endocrine balance and relieving climacteric syndrome and irregular menstruation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101787432B1 (en) | Method for manufacturing oriental medicine composition which improves menorrhagia and dysmenorrhea comprising fermented velvet antler and yeast hydrolysate | |
| CN104306959B (en) | One treats osteoporotic pharmaceutical composition and preparation method thereof | |
| CN102846906B (en) | Medicament for treating premature ovarian failure and preparation method thereof | |
| CN102172269A (en) | Hidegelatin fabricated food with beautification function | |
| KR101855821B1 (en) | Composition for relieving of menopausal symptoms and improving blood circulation | |
| CN109700011A (en) | A kind of health food and preparation method thereof improving sleep | |
| CN113616709A (en) | A Chinese medicinal composition for treating male infertility, and its preparation method | |
| DE60129282T2 (en) | Health food | |
| CN107048386A (en) | A kind of sexual function adjusts health food | |
| CN100352464C (en) | A medicine for treating osteoporosis | |
| CN103948791B (en) | A kind of Chinese medicine composition of reducing blood lipid and preparation method thereof | |
| CN109350624A (en) | Female health composition, preparation containing NMN and DHEA and the preparation method and application thereof | |
| CN110367537A (en) | A kind of functional food and preparation method thereof improving menopausal syndrome | |
| CN108208456A (en) | A kind of feed addictive for improving laying rate of laying hen and preparation method thereof | |
| CN104489172A (en) | Acanthopanax health tea for improving immunity and preparation method thereof | |
| CN105250556A (en) | Traditional Chinese medicine drug for treating polycystic ovarian syndrome | |
| CN110237117A (en) | A kind of soft capsule and preparation method thereof of Menopause anti-aging | |
| KR101822834B1 (en) | Composition for improving menopausal symptom | |
| CN105796845A (en) | Application of medicine composition in preparing medicine for treating female climacteric syndromes | |
| CN103919961B (en) | Middle and old age kidney-jing deficiency and kidney yang deficiency treatment traditional Chinese medicine preparation and preparation method thereof | |
| CN101380387A (en) | Composition for treating climacteric metancholia and preparation method thereof | |
| CN107801995A (en) | A kind of asparagus composition for preventing and nursing one's health menopause symptom and its application | |
| CN107198727A (en) | A kind of pharmaceutical composition of beautifying face and moistering lotion promoting blood circulation for regulating menstruation and preparation method thereof | |
| CN104257839B (en) | A kind of Chinese medicine composition with hypoglycemic protection blood vessel endothelium effect and preparation method thereof | |
| CN105213748A (en) | A kind of pharmaceutical composition for the treatment of female dimacteric syndrome and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191025 |